It’s been six months since a drug developer went public on the US stock exchanges. The last IPO was Feb. 13, when Aardvark Therapeutics debuted on the Nasdaq. Its share price $AARD is about 30% lower today. This is one of the longest biotech IPO dry spells since the Great Recession, when 21 months separated Wall Street listings for biopharma companies. Ironically, that lull ended 16 years ago on a day in August. By comparison, there were more than 50 biotech IPOs from Feb. 13 to Aug. 13 in 2021, when it felt like nearly any company could land a ticker. However, many investors were burned during that period, and industry leaders agreed that the pace was unsustainable.
Read the full article: Biotech Industry Goes Six Months Without an IPO //
Source: https://endpoints.news/biotech-industry-goes-six-months-without-an-ipo/